Lilly Laid Groundwork For Abbott's Defeat Of J&J's Patent Verdict On Humira
Abbott Laboratories had reason to thank Eli Lilly & Co. when the U.S. Court of Appeals for the Federal Circuit overturned a record $1.67-billion jury verdict that Abbott's Humira infringed a Johnson & Johnson patent.
You may also be interested in...
Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.
Sanofi attorneys describe three possible outcomes of fight over injunction and validity of Repatha patents, and contrast litigation to other patent disputes where innovators did not seek removal of innovator product from market.
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.